FluoGuide A/S Jun 30 2026 Reviewed FluoGuide A/S, a biotech company maximizing surgical outcomes in oncology by lighting up cancer, today announced positive results from the first part of its ongoing FG001-CT-005 Phase 2 trial evaluating FG001 for surgical guidance in patients with oral head and neck cancer. Key data: 19 patients screened, 15 patients enrolled and completed surgery, completing the first part of the trial and allowing release of the primary endpoint results. The primary endpoint